Published in Blood on April 29, 2011
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol (2014) 1.18
Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr Opin Immunol (2011) 1.17
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Natural killer cells: role in local tumor growth and metastasis. Biologics (2012) 0.94
In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census. Oncoimmunology (2012) 0.92
Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother (2012) 0.89
The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling. J Immunol (2014) 0.88
Characterization of Ewing sarcoma associated cancer/testis antigens. Cancer Biol Ther (2013) 0.81
Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res (2014) 0.81
A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. AAPS J (2014) 0.81
Emerging cancer vaccines: the promise of genetic vectors. Cancers (Basel) (2011) 0.81
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 0.81
Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity. J Immunol Res (2014) 0.81
2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci (2015) 0.79
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Front Immunol (2012) 0.79
Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). J Gastrointest Oncol (2016) 0.79
Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother (2014) 0.79
Enhanced autoimmunity associated with induction of tumor immunity in thyroiditis-susceptible mice. Thyroid (2013) 0.79
Enhanced CD8 T cell responses through GITR-mediated costimulation resolve chronic viral infection. PLoS Pathog (2015) 0.77
Anti-cancer vaccines - a one-hit wonder? Yale J Biol Med (2014) 0.76
Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. Hum Vaccin Immunother (2016) 0.76
Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination. Hum Vaccin Immunother (2015) 0.75
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. Cancer Gene Ther (2017) 0.75
Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression. Oncotarget (2016) 0.75
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. Cancer Immunol Res (2016) 0.75
Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases. J Investig Med High Impact Case Rep (2016) 0.75
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. J Natl Cancer Inst (2017) 0.75
Perspective on the dynamics of cancer. Theor Biol Med Model (2017) 0.75
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol (2007) 2.43
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
Activation of NK cell cytotoxicity. Mol Immunol (2005) 2.03
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol (2002) 1.92
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol (2001) 1.70
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood (2011) 1.69
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res (2012) 1.67
Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol (2010) 1.58
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol (2002) 1.50
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma (2014) 1.47
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood (2012) 1.43
Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol (2005) 1.40
CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 1.36
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33
Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. Biochem Biophys Res Commun (2005) 1.32
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A (2013) 1.32
Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol (2002) 1.31
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology (2013) 1.29
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol (2004) 1.24
Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res (2007) 1.19
Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res (2010) 1.16
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A (2005) 1.14
Gene modification strategies to induce tumor immunity. Immunity (2005) 1.12
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood (2005) 1.10
Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function. Blood (2007) 1.10
Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res (2010) 1.08
Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol (2013) 1.08
Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res (2007) 1.06
Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy (2011) 1.05
Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis. J Immunol (2011) 1.05
The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene. J Exp Med (2004) 1.05
cAMP response element binding protein is required for mouse neural progenitor cell survival and expansion. Stem Cells (2009) 1.05
Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res (2010) 1.04
A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther (2004) 1.03
Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate (2004) 1.03
Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res (2008) 1.03
Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol (2008) 1.00
CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol (2010) 0.98
Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology (2013) 0.98
Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation (2005) 0.98
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma (2014) 0.96
Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother (2011) 0.95
Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. Clin Cancer Res (2009) 0.95
Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res (2007) 0.94
Perforin-mediated suppression of B-cell lymphoma. Proc Natl Acad Sci U S A (2009) 0.94
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med (2010) 0.94
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther (2004) 0.94
Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: Harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity. J Immunother (2003) 0.93
Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer Immunol Immunother (2010) 0.93
Enhancing adoptive immunotherapy of cancer. Expert Opin Biol Ther (2010) 0.92